Cargando…

An Oncolytic Vaccinia Virus Armed with GM-CSF and IL-24 Double Genes for Cancer Targeted Therapy

PURPOSE: Targeted oncolytic vaccinia virus is an attractive candidate for cancer therapy due to its replication causing lysis of infected tumor cells as well as a delivery vector to overexpress therapeutic transgenes. This study constructed a novel oncolytic vaccinia virus carrying granulocyte-macro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, Lili, Yang, Xue, Fan, Jun, Ding, Yuedi, Peng, Ying, Xu, Dong, Huang, Biao, Hu, Zhigang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196195/ https://www.ncbi.nlm.nih.gov/pubmed/32425553 http://dx.doi.org/10.2147/OTT.S249816

Ejemplares similares

Oncolytic therapy with vaccinia virus carrying IL-24 for hepatocellular carcinoma
por: Deng, Lili, et al.
Publicado: (2022)

IL-24-Armed Oncolytic Vaccinia Virus Exerts Potent Antitumor Effects via Multiple Pathways in Colorectal Cancer
por: Deng, Lili, et al.
Publicado: (2021)

Target Therapy With Vaccinia Virus Harboring IL-24 For Human Breast Cancer
por: Deng, Lili, et al.
Publicado: (2020)

Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9
por: Deng, Lili, et al.
Publicado: (2017)

Antitumor efficacy of cytosine deaminase-armed vaccinia virus plus 5-fluorocytosine in colorectal cancers
por: Ding, Yuedi, et al.
Publicado: (2020)

IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy
por: Chen, Tianyue, et al.
Publicado: (2021)

Luteolin enhances the antitumor efficacy of oncolytic vaccinia virus that harbors IL‐24 gene in liver cancer cells
por: Wang, Chunming, et al.
Publicado: (2020)

Optimizing DC Vaccination by Combination With Oncolytic Adenovirus Coexpressing IL-12 and GM-CSF
por: Zhang, Song-Nan, et al.
Publicado: (2011)

Evaluation of Tumor Specificity and Immunity of Thymidine Kinase-Deleted Vaccinia Virus Guang9 Strain
por: Ding, Yuedi, et al.
Publicado: (2020)

Antitumor Efficacy of Oncolytic Herpes Virus Type 1 Armed with GM-CSF in Murine Uveal Melanoma Xenografts
por: Liu, Sisi, et al.
Publicado: (2020)

Intravesical immunotherapy with a GM-CSF armed oncolytic vesicular stomatitis virus improves outcome in bladder cancer
por: Rangsitratkul, Coby, et al.
Publicado: (2022)

Bioluminescence imaging of a tumor-selective, thymidine kinase-defective vaccinia virus Guang9 strain after intratumoral or intraperitoneal administration in mice
por: Ding, Yuedi, et al.
Publicado: (2017)

Correction: IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy
Publicado: (2021)

Combined anti-tumor efficacy of somatostatin fusion protein and vaccinia virus on tumor cells with high expression of somatostatin receptors
por: Fan, Jun, et al.
Publicado: (2022)

Antitumor activity of recombinant oncolytic vaccinia virus with human IL2
por: Liu, Liqiong, et al.
Publicado: (2022)

Theranostic Potential of Oncolytic Vaccinia Virus
por: Rojas, Juan J, et al.
Publicado: (2012)

Immunotherapeutic Potential of Oncolytic Vaccinia Virus
por: Thorne, Steve H.
Publicado: (2014)

Oncolytic adenovirus armed with IL-24 Inhibits the growth of breast cancer in vitro and in vivo
por: Zhu, Wei, et al.
Publicado: (2012)

Oncolytic Vaccinia Virus in Lung Cancer Vaccines
por: Truong, Cao-Sang, et al.
Publicado: (2022)

Global trends of Vaccinia oncolytic virus therapy over the past two decades: Bibliometric and visual analysis
por: Bo, Liu, et al.
Publicado: (2023)

Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment
por: Fend, Laetitia, et al.
Publicado: (2015)

A novel cocktail therapy based on quintuplet combination of oncolytic herpes simplex virus-2 vectors armed with interleukin-12, interleukin-15, GM-CSF, PD1v, and IL-7 × CCL19 results in enhanced antitumor efficacy
por: Hu, Han, et al.
Publicado: (2022)

Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy
por: Kochneva, Galina, et al.
Publicado: (2016)

Beclin1-armed oncolytic Vaccinia virus enhances the therapeutic efficacy of R-CHOP against lymphoma in vitro and in vivo
por: Xie, Shufang, et al.
Publicado: (2021)

GM-CSF Signalling Boosts Dramatically IL-1Production
por: Khameneh, Hanif Javanmard, et al.
Publicado: (2011)

Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety
por: Ge, Yan, et al.
Publicado: (2020)

Oncolytic properties of non-vaccinia poxviruses
por: Ricordel, Marine, et al.
Publicado: (2018)

Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia
por: Wang, Weiyi, et al.
Publicado: (2021)

Determinants of combination GM-CSF immunotherapy and oncolytic virotherapy success identified through in silico treatment personalization
por: Cassidy, Tyler, et al.
Publicado: (2019)

Targeting hematologic malignancies with oncolytic vaccinia virus constructs
por: Chen, Nanhai, et al.
Publicado: (2013)

GM-CSF in inflammation
por: Hamilton, John A.
Publicado: (2019)

Deletion of immunomodulatory genes as a novel approach to oncolytic vaccinia virus development
por: Ho, Tiffany Y., et al.
Publicado: (2021)

Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model
por: Lee, J-H, et al.
Publicado: (2009)

GM-CSF: A Double-Edged Sword in Cancer Immunotherapy
por: Kumar, Anil, et al.
Publicado: (2022)

IL-27, but not IL-35, inhibits neuroinflammation through modulating GM-CSF expression
por: Casella, Giacomo, et al.
Publicado: (2017)

Innate Immune Modulation by GM-CSF and IL-3 in Health and Disease
por: Borriello, Francesco, et al.
Publicado: (2019)

G-CSF and GM-CSF in clinical trials.
por: Antman, K. H.
Publicado: (1990)

The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism
por: Foloppe, Johann, et al.
Publicado: (2019)

Oncolytic vaccinia therapy of squamous cell carcinoma
por: Yu, Zhenkun, et al.
Publicado: (2009)

Polymeric Cups for Cavitation-mediated Delivery of Oncolytic Vaccinia Virus
por: Myers, Rachel, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1aib8uk99uk8eanbgshbqlab6s